ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Files An 8-K Financial Statements and ExhibitsItem 9.01
Story continues below
|99.1||Press Release dated January9, 2018.|
ZIOPHARM ONCOLOGY INC ExhibitEX-99.1 2 d444139dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare Conference – Controlled IL-12 advancing as drug platform as monotherapy and in combination with OPDIVO® (nivolumab) – Non-viral T-cell platform shows potential for efficacy,…To view the full exhibit click
About ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.